ArticleAvicenna journal of phytomedicine
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The beneficial effect of Materials and Methods: Thirty-two rats with regular estrous cycles were enrolled as controls, polycystic ovary syndrome (PCOS), and two treatment groups. PCOS was induced by estradiol valerate. The treatment groups (T1 &T2) received VE (150 or 200 mg/kg body weight, respectively) for 30 days following PCOS induction. Serum and left ovary were used to assess hormone levels and Results: In the T2 group, a significant decrease in estradiol (E2, testosterone, and AMH levels (p=0.028) was observed with no significant change in DHEA (p=0.967) in comparison with the PCOS group. AMH in the serum was significantly higher in the PCOS group than in all the other groups (p=0.021). The level of progesterone was not considerably changed between treatments and the PCOS group (p=0.11). The expression of Conclusion: The endocrine profile and gene expression were improved in the rat ovary following administration of VE, and therefore, the therapeutic effect of VE may be expected in PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.